The cast of molecular characters in Parkinson's disease: Felons, conspirators, and suspects

Annals of the New York Academy of Sciences

Volumn 991, Issue , 2003, Pages 80-92

  Lim, Kah Leong ^a   Dawson, Valina L ^b   Dawson, Ted M ^b  

^a NATIONAL NEUROSCIENCE INSTITUTE   (Singapore)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Parkin; Parkinson's disease; Ubiquitin proteasome system; Ubiquitination; UCHL1; synuclein

Indexed keywords

ALPHA SYNUCLEIN; BRAIN PROTEIN; GENE PRODUCT; HYDROLASE; PARKIN; PROTEASOME; SYNPHILIN 1; UBIQUITIN CARBOXY TERMINAL HYDROLASE L1; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG;

BIOACCUMULATION; CELL DEATH; CELL LOSS; CHEMICAL REACTION; CLINICAL FEATURE; CONFERENCE PAPER; DOPAMINERGIC NERVE CELL; ENZYME ACTIVITY; GENE MUTATION; HUMAN; LEWY BODY; NEURITE; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN METABOLISM; UBIQUITINATION;

EID: 0038051352     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2003.tb07465.x     Document Type: Conference Paper

References (59)

1. LANG, A.E. & A.M. LOZANO. 1998. Parkinson's disease. First of two parts. N. Engl. J. Med. 339: 1044-1053.
2. LANG, A.E. & A.M. LOZANO. 1998. Parkinson's disease. Second of two parts. N. Engl. J. Med. 339: 1130-1143.
3. LIM, K.L., V.L. DAWSON & T.M. DAWSON. 2002. The genetics of Parkinson's disease. Curr. Neurol. Neurosci. Rep. 2: 439-446.
4. PICKART, C.M. 2001. Mechanisms underlying ubiquitination. Annu. Rev. Biochem. 70: 503-533.
5. SHIMURA, H., N. HATTORI, S. KUBO, et al. 2000. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat. Genet. 25: 302-305.
6. IMAI, Y., M. SODA & R. TAKAHASHI. 2000. Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity. J. Biol. Chem. 275: 35661-35664.
7. ZHANG, Y., J. GAO, K.K. CHUNG, et al. 2000. Parkin functions as an E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc. Natl. Acad. Sci. USA 97: 13354-13359.
8. KRUGER, R., O. EBERHARDT, O. RIESS, et al. 2002. Parkinson's disease: one biochemical pathway to fit all genes? Trends Mol. Med. 8: 236-240.
9. POLYMEROPOULOS, M.H., C. LAVEDAN, E. LEROY, et al. 1997. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276: 2045-2047.
10. KRUGER, R., W. KUHN, T. MULLER, et al. 1998. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 18: 106-108.
11. SPILLANTINI, M.G., M.L. SCHMIDT, V.M. LEE, et al. 1997. Alpha-synuclein in Lewy bodies. Nature 388: 839-840.
12. GOEDERT, M. 2001. Alpha-synuclein and neurodegenerative diseases. Nat. Rev. Neurosci. 2: 492-501.
13. ABELIOVICH, A., Y. SCHMITZ, I. FARINAS, et al. 2000. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25: 239-252
14. DAWSON, T., A. MANDIR & M. LEE. 2002. Animal models of PD: pieces of the same puzzle? Neuron 35: 219-222.
15. SPIRA, P.J., D.M. SHARPE, G. HALLIDAY, et al. 2001. Clinical and pathological features of a Parkinsonian syndrome in a family with an Ala53Thr alpha-synuclein mutation. Ann. Neurol. 49: 313-319.
16. LO BIANCO, C., J.L. RIDET, B.L. SCHNEIDER, et al. 2002. alpha-Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proc. Natl. Acad. Sci. USA 99: 10813-10818.
17. KIRIK, D., C. ROSENBLAD, C. BURGER, et al. 2002. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J. Neurosci. 22: 2780-2791.
18. GIASSON, B.I., K. URYU, J.Q. TROJANOWSKI, et al. 1999. Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro. J. Biol. Chem. 274: 7619-7622.
19. GIASSON, B.I., J.E. DUDA, S.M. QUINN, et al. 2002. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron 34: 521-533.
20. LEE, M.K., W. STIRLING, Y. Xu, et al. 2002. Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 → Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc. Natl. Acad. Sci. USA 99: 8968-8973.
21. PAXINOU, E., Q. CHEN, M. WEISSE, et al. 2001. Induction of alpha-synuclein aggregation by intracellular nitrative insult. J. Neurosci. 21: 8053-8061.
22. SHERER, T.B., R. BETARBET, A.K. STOUT, et al. 2002. An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. J. Neurosci. 22: 7006-7015.
23. LEE, H.J., S.Y. SHIN, C. CHOI, et al. 2002. Formation and removal of alpha-synuclein aggregates in cells exposed to mitochondrial inhibitors. J. Biol. Chem. 277: 5411-5417.
24. OKOCHI, M., WALTER, J., KOYAMA, A., et al. 2000. Constitutive phosphorylation of the Parkinson's disease associated alpha-synuclein. J. Biol. Chem. 275: 390-397.
25. FUJIWARA, H., M. HASEGAWA, N. DOHMAE, et al. 2002. alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 4: 160-164.
26. GOLDBERG, M.S. & P.T. LANSBURY, JR. 2000. Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease? Nat. Cell Biol. 2: E115-119.
27. CONWAY, K.A., S.J. LEE, J.C. ROCHET, et al. 2000. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl. Acad. Sci. USA 97: 571-576.
28. CONWAY, K.A., J.C. ROCHET, R.M. BIEGANSKI, et al. 2001. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 294: 1346-1349.
29. XU, J., S.Y. KAO, F.J. LEE, et al. 2002. Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat. Med. 8: 600-606.
30. VAN HEMERT, M.J., H.Y. STEENSMA & G.P. VAN HEUSDEN. 2001. 14-3-3 proteins: key regulators of cell division, signalling, and apoptosis, Bioessays 23: 936-946.
31. WELCH, K. & J. YUAN. 2002. Releasing the nerve cell killers. Nat. Med. 8: 564-565.
32. SHIMURA, H., M.G. SCHLOSSMACHER, N. HATTORI, et al. 2001. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science 293: 263-269.
33. CHUNG, K.K., Y. ZHANG, K.L. LIM, et al. 2001. Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. Nat. Med. 7: 1144-1150.
34. IMAI, Y., M. SODA, H. INOUE, et al. 2001. An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin. Cell 105: 891-902.
35. BEITES, C.L., H. XIE, R. BOWSER, et al. 1999. The septin CDCrel-1 binds syntaxin and inhibits exocytosis. Nat. Neurosci. 2: 434-439.
36. PENG, X.R., Z. JIA, Y. ZHANG, et al. 2002. The septin CDCrel-1 is dispensable for normal development and neurotransmitter release. Mol. Cell Biol. 22: 378-387.
37. ENGELENDER, S., Z. KAMINSKY, X. GUO, et al. 1999. Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions. Nat. Genet. 22: 110-114.
38. WAKABAYASHI, K., S. ENGELENDER, M. YOSHIMOTO, et al. 2000. Synphilin-1 is present in Lewy bodies in Parkinson's disease. Ann. Neurol. 47: 521-523.
39. LIM, K.L., Y. TANAKA & Y. ZHANG. 2002. Parkin mediates lysine-63 (K-63)-linked ubiquitination of synphilin-1: Implications for Lewy Body formation. Soc. Neurosci. Abst.
40. SCOTT, W.K., M.A. NANCE, R.L. WATTS, et al. 2001. Complete genomic screen in Parkinson disease: evidence for multiple genes. JAMA 286: 2239-2244.
41. MARTIN, E.R., W.K. SCOTT, M.A. NANCE, et al. 2001. Association of single-nucleotide polymorphisms of the tau gene with late-onset Parkinson disease. JAMA 286: 2245-2250.
42. VAN DE WARRENBURG, B.P., M. LAMMENS, C.B. LUCKING, et al. 2001. Clinical and pathologic abnormalities in a family with parkinsonism and parkin gene mutations. Neurology 56: 555-557.
43. DAWSON, T.M. 2000. New animal models for Parkinson's disease. Cell 101: 115-118.
44. CHUNG, K.K., V.L. DAWSON & T.M. DAWSON. 2001. The role of the ubiquitin-proteasomal pathway in Parkinson's disease and other neurodegenerative disorders. Trends Neurosci. 24: S7-14.
45. FARRER, M., P. CHAN, R. CHEN, et al. 2001. Lewy bodies and parkinsonism in families with parkin mutations. Ann. Neurol. 50: 293-300.
46. AULUCK, P.K., H.Y. CHAN, J.Q. TROJANOWSKI, et al. 2002. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science 295: 865-868.
47. IMAI, Y., M. SODA, S. HATAKEYAMA, et al. 2002. CHIP is associated with Parkin, a gene responsible for familial Parkinson's disease, and enhances its ubiquitin ligase activity. Mol. Cell 10: 55-67.
48. WEST, A.M. 2002. Complex relationship between Parkin mutations and Parkinson disease. Am. J. Med. Genet. 114: 584-591.
49. LEROY, E., R. BOYER, G. AUBURGER, et al. 1998. The ubiquitin pathway in Parkinson's disease. Nature 395: 451-452.
50. LINCOLN, S., J. VAUGHAN, N. WOOD, et al. 1999. Low frequency of pathogenic mutations in the ubiquitin carboxy-terminal hydrolase gene in familial Parkinson's disease. Neuroreport 10: 427-429.
51. MARAGANORE, D.M., M.J. FARRER, J.A. HARDY, et al. 1999. Case-control study of the ubiquitin carboxy-terminal hydrolase L1 gene in Parkinson's disease. Neurology 53: 1858-1860.
52. LI, M., D. CHEN, A. SHILOH, et al. 2002. Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature 416: 648-653.
53. VAUGHAN, J.R., M.B. DAVIS & N.W. WOOD. 2001. Genetics of Parkinsonism: a review. Ann. Hum. Genet. 65: 111-126.
54. RAMSDEN, D.B., R.B. PARSONS, S.L. HO, et al. 2001. The aetiology of idiopathic Parkinson's disease. Mol. Pathol. 54: 369-380.
55. HASHIMOTO, M., E. ROCKENSTEIN & M. MANTE. 2001. beta-Synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor. Neuron 32: 213-223
56. MASLIAH, E., E. ROCKENSTEIN, I. VEINBERGS, et al. 2000. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 287: 1265-1269.
57. MATSUOKA, Y., M. VILA, S. LINCOLN, et al. 2001. Lack of nigral pathology in transgenic mice expressing human alpha-synuclein driven by the tyrosine hydroxylase promoter. Neurobiol. Dis. 8: 535-539.
58. RICHFIELD, E.K., M.J. THIRUCHELVAM, D.A. CORY-SLECHTA, et al. 2002. Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice. Exp. Neurol. 175: 35-48.
59. VAN DER PUTTEN, H., K.H. WIEDERHOLD, A. PROBST, et al. 2000. Neuropathology in mice expressing human alpha-synuclein. J. Neurosci. 20: 6021-6029.